<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Aptos;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
font-size:11.0pt;
font-family:"Aptos",sans-serif;
mso-ligatures:standardcontextual;
mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#467886;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Aptos",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:11.0pt;
mso-fareast-language:EN-US;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body link="#467886" vlink="#96607D" style="word-wrap:break-word">
<div class="WordSection1">
<p class="MsoNormal"><b><span lang="EN-GB">A </span>Marie Skłodowska-Curie </b><b><span lang="EN-GB">(MCSA) postdoctoral position at Lund University Medical Faculty, Sweden.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span lang="EN-GB">Structural and biophysical studies of the molecular pathology underlying transthyretin amyloidosis (ATTR amyloidosis)
<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span lang="EN-GB"><o:p> </o:p></span></b></p>
<p class="MsoNormal">Transthyretin <span lang="EN-GB">(TTR) amyloidosis is a serious disease that has devastating effects on human health. This occurs when the transthyretin protein, which normally functions as a blood transporter of the hormone thyroxine and
retinal binding protein, misfolds and forms amyloid fibrils that obstruct crucial tissues such as the heart or nervous tissue.
<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-GB"><o:p> </o:p></span></p>
<p class="MsoNormal">The project will focus on probing the molecular factors underlying th<span lang="EN-GB">e
</span>instability<span lang="EN-GB"> of TTR </span> (see for example <a href="https://www.nature.com/articles/s41467-019-08609-z/">
https://www.nature.com/articles/s41467-019-08609-z/</a>), and in understanding the pathway that link<span lang="EN-GB">s</span> the functional and pathological forms of the protein.
<span lang="EN-GB">There is also interest in studying the effect of candidate drugs that may slow or prevent amyloid formation.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-GB"><o:p> </o:p></span></p>
<p class="MsoNormal">Techniques involved will include X-ray and neutron crystallography, small-angle scattering (SAXS & SANS), and cryo-EM<span lang="EN-GB">. The successful applicant will have good access to advanced international facility centres for synchrotron
X-ray and neutron beams such as </span><a href="https://www.maxiv.lu.se/"><span lang="EN-GB">MAX IV</span></a><span lang="EN-GB">,
</span><a href="https://www.ill.eu/"><span lang="EN-GB">ILL</span></a><span lang="EN-GB">,
</span><a href="https://esrf.fr/"><span lang="EN-GB">ESRF</span></a><span lang="EN-GB">,
</span><a href="https://www.isis.stfc.ac.uk/"><span lang="EN-GB">ISIS</span></a><span lang="EN-GB">, and during the course of this project,
</span><a href="https://ess.eu/"><span lang="EN-GB">ESS</span></a><span lang="EN-GB">.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-GB"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-GB">The project is resourced through the MCSA AMBER project – for further details and application instructions, see
</span><a href="https://www.ambercofund.eu/"><span lang="EN-GB">https://www.ambercofund.eu/</span></a><span lang="EN-GB">.
<b>Applicants are strongly encouraged to contact the PI for the project, Professor Trevor Forsyth (</b></span><a href="mailto:trevor.forsyth@med.lu.se"><b><span lang="EN-GB">trevor.forsyth@med.lu.se</span></b></a><b><span lang="EN-GB">) before applying</span></b><span lang="EN-GB">.
<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-GB">Deadline: 28<sup>th</sup> September 2025.<o:p></o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>